Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 0.04 below Abvc Biopharma Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Quick Ratio than Abvc Biopharma Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 2939 to 3869.

Explain Quick Ratio?
How much Cash & cash equivalents ABVC�s has?
What are ABVC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ABVC Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q3	(Sep 30 2025) Q2	(Jun 30 2025) Q1	(Mar 31 2025) Q3
Y / Y Current Liabilities Change	-19.87 %	-2.4 %	-0.63 %	8.36 %	25.5 %
Y / Y Cash & cash equivalent Change	-6.79 %	177.19 %	-1.06 %	171.45 %	-64.55 %
Quick Ratio MRQ	0.04	0.12	0.04	0.07	0.03
ABVC's Total Ranking	# 3869	# 2939	# 3364	# 3247	# 3759
Seq. Current Liabilities Change	-12.51 %	-5.28 %	-0.38 %	-2.94 %	6.57 %
Seq. Cash & cash equivalent Change	-72.85 %	189.93 %	-43.27 %	108.72 %	-19.26 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 424
Healthcare Sector	# 856
Overall Market	# 3869

Quick Ratio Statistics
High	Average	Low
153.15	5	0
(Mar 31 2016)		(Sep 30 2013)

Financial Statements
Abvc Biopharma Inc 's Current Liabilities	$ 5 Millions	Visit ABVC's Balance sheet
Abvc Biopharma Inc 's Cash & cash equivalent	$ 0 Millions	Visit ABVC's Balance sheet
Source of ABVC's Sales		Visit ABVC's Sales by Geography

Cumulative Abvc Biopharma Inc 's Quick Ratio

ABVC's Quick Ratio for the trailling 12 Months

ABVC Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-4.01 %	6.92 %	10.01 %	34.13 %	32.97 %
Y / Y Cash & cash equivalent TTM Growth	81.64 %	27.87 %	-35.6 %	-65.41 %	-80.85 %
Quick Ratio TTM	0.07	0.06	0.05	0.05	0.04
Total Ranking TTM	# 3988	# 2613	# 3320	# 3117	# 3336
Seq. Current Liabilities TTM Growth	-5.16 %	-0.58 %	-0.16 %	1.97 %	5.64 %
Seq. Cash & cash equivalent TTM Growth	-0.88 %	39.83 %	-0.23 %	31.36 %	-30.22 %

Quick ratio ranking by company, industry and sector >> Back to ABVC Financial Strength Comparisons >> Go to Compare ABVC Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Abvc Biopharma Inc 's average Cash & cash equivalent, this led to increase in in Abvc Biopharma Inc 's Quick Ratio to 0.07, Quick Ratio remained below ABVC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Abvc Biopharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2613 to 3988.

Explain Quick Ratio?
How much Cash & cash equivalents ABVC�s has?
What are ABVC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 437
Healthcare Sector	# 894
Within the Market	# 3988

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.29	0.33	0.01
(Jun 30 2022)		(Dec 31 2018)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Bioxytran Inc	0.09	$ 0.463 Millions	$ 5.010 Millions
Dr Reddy s Laboratories Limited	0.09	$ 164.000 Millions	$ 1,787.000 Millions
Citius Pharmaceuticals Inc	0.08	$ 4.590 Millions	$ 55.016 Millions
Summit Therapeutics Inc	0.08	$ 8.238 Millions	$ 99.075 Millions
Igc Pharma Inc	0.08	$ 0.235 Millions	$ 2.873 Millions
Cv Sciences Inc	0.08	$ 0.309 Millions	$ 3.799 Millions
Hcw Biologics Inc	0.06	$ 1.229 Millions	$ 19.959 Millions
Os Therapies Incorporated	0.05	$ 0.918 Millions	$ 18.331 Millions
Citius Oncology Inc	0.04	$ 2.633 Millions	$ 58.812 Millions
Abvc Biopharma Inc	0.04	$ 0.203 Millions	$ 5.393 Millions
IMPACT BIOMEDICAL INC.	0.03	$ 0.020 Millions	$ 0.584 Millions
Provectus Biopharmaceuticals Inc	0.03	$ 0.224 Millions	$ 7.242 Millions
Evofem Biosciences Inc	0.03	$ 2.379 Millions	$ 78.752 Millions
Gridai Technologies Corp	0.02	$ 0.386 Millions	$ 16.232 Millions
Aditxt Inc	0.02	$ 0.269 Millions	$ 11.452 Millions
China Pharma Holdings Inc	0.02	$ 0.168 Millions	$ 7.268 Millions
Northwest Biotherapeutics Inc	0.02	$ 1.786 Millions	$ 82.973 Millions
Lakewood-Amedex Biotherapeutics Inc.	0.02	$ 0.012 Millions	$ 0.548 Millions
Zyversa Therapeutics Inc	0.02	$ 0.303 Millions	$ 14.739 Millions
Sunshine Biopharma Inc	0.01	$ 0.072 Millions	$ 5.878 Millions
Lftd Partners Inc	0.01	$ 0.054 Millions	$ 4.543 Millions
Semnur Pharmaceuticals Inc	0.01	$ 0.103 Millions	$ 10.380 Millions
Neonc Technologies Holdings Inc	0.01	$ 0.139 Millions	$ 16.288 Millions

Date modified: 2026-09-12T06:12:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.